The primary market witnessed improved investor appetite on the final day of bidding, with both Park Medi World and Nephrocare Health Services attracting healthy subscriptions.
Park Medi World led the day with 8.10 times overall subscription, while Nephrocare Health Services gathered strong last-day momentum to reach 13.96 times subscription. Institutional and non-institutional investors drove most of the traction in both offerings, lifting market sentiment ahead of their listing.
Park Medi World IPO subscription status
Park Medi World’s public offer saw solid participation across investor categories. Qualified institutional buyers subscribed 11.48 times, indicating robust institutional confidence. The non-institutional investor segment stood out with a subscription rate of 15.15 times, while the retail segment registered 3.16 times, reflecting balanced interest from individual investors.
The comprised a fresh issue of shares worth ₹770 crore and an OFS of shares valued at ₹150 crore by promoter Ajit Gupta. The ₹920-crore IPO had a price band of ₹154-162 per share. Ahead of the IPO, the company raised ₹276 from anchor investors. The company will use the proceeds to repay debt, to develop a new hospital and expand an existing one through its subsidiaries, Park Medicity (NCR) and Blue Heavens. It will also be allocated to unspecified acquisitions and general corporate purposes.
Nephrocare Health Services IPO Subscription Status
Nephrocare Health Services witnessed a strong surge in demand on its final day after muted interest on the first two days. The issue had reached 13.96 times the overall subscription. QIBs subscribed 27.47 times, indicating a turnaround in institutional sentiment. The NII category was subscribed to 24.27 times, demonstrating strong investor confidence. The retail portion remained moderate at 2.31 times, while the employee quota saw a subscription of 2.67 times.
The ₹871 crore IPO of this Hyderabad-based company comprised a fresh issue of 353.4 crore shares aggregating to ₹871 crore and an OFS of 1.2 crore shares valued at ₹517.6 crore. The company raised ₹260 crore from anchor investors. The funds will be used to repay debts, open new dialysis clinics in India and for general corporate purposes.
Both IPOs close today with encouraging institutional and NII interest, setting the stage for potentially healthy market debuts on December 17, 2025.